Globe Life

GL · NYSE

$169.72+$1.87 (+1.11%)TodayMarket closed · Oct 20, 7:38 PM ET

Prev close $167.85

GL analyst rating

BuyConsensus of 12 analysts over the last 12 months. 83% rate it a buy.

Strong buy0
Buy10
Hold2
Underperform0
Sell0

12-month price target · 17 analysts

Average $199.26 (+17.4% upside)

Low: $167.66
Now: $169.72
High: $236.25

Upgrades and downgrades

The latest rating actions, newest first

GL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 15, 2026	Maintains	Overweight	$193.00 → $195.00	81%
Wells Fargo	Oct 12, 2026	Maintains	Overweight	$190.00 → $191.00	75%
Morgan Stanley	Oct 5, 2026	Maintains	Overweight	$208.00 → $197.00	49%
Keefe, Bruyette & Woods	Jul 24, 2026	Maintains	Outperform	$192.00 → $190.00	71%
TD Cowen	Jul 22, 2026	Maintains	Buy	$215.00 → $225.00	54%
JP Morgan	Jul 21, 2026	Maintains	Overweight	$181.00 → $201.00	81%
Piper Sandler	Jul 15, 2026	Maintains	Overweight	$175.00 → $200.00	73%
Evercore ISI Group	Jul 13, 2026	Maintains	In-Line	$157.00 → $176.00	59%
Keefe, Bruyette & Woods	Jul 13, 2026	Maintains	Outperform	$180.00 → $192.00	71%
Jefferies	Jul 10, 2026	Maintains	Hold	$147.00 → $166.00	76%

The case for and against

Updated Jul 30, 2026

Bull case

Globe Life is expected to have sustained low-double-digit EPS growth over time, driven by mid-single-digit premium growth, growth in net investment income, and active share repurchases with expense leverage providing an additional tailwind. The company's attractive business model generates solid, consistent top- and bottom-line growth with below-peer underwriting and balance sheet risk and market sensitivity. Additionally, the recent Bermuda reinsurance structure is likely to provide long-term upside, and the stock currently trades below its historical valuation multiples, making it an attractive entry point for investors. However, downside risks include a reversal of recent favorable mortality trends and slower agent count growth.

Bear case

Globe Life is a top pick in the U.S. life insurance sector due to its attractive business model, expected low double-digit EPS growth, and potential for FCF upside from Bermuda operations. The company has also been actively repurchasing its own stock, and management is confident in sustaining long-term growth through increased agent count, higher sales, and expense leverage. However, there are risks such as lower interest rates, credit concerns, and weak equity markets that could negatively impact the company's financials. The recent short report and volatility in a secondary product line have also affected the stock's valuation, but it is expected to recover in the future.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.